SB-649,868

SB-649,868
(IUPAC) ime
	N-([(2S)-1-([5-(4-fluorofenil)-2-metil-4-tiazolil]karbonil)-2-piperidinil]metil)-4-benzofurankarboksamid
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	25195495
ChEMBL	CHEMBL1272307
Hemijski podaci
Formula	C26H24FN3O3S
Mol. masa	477,549 g/mol (slobodna baza)
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1 ; Key: ZJXIUGNEAIHSBI-IBGZPJMESA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

SB-649,868 je antagonist oreksinskog receptora u razvoju od strane kompanije GlaksoSmitKlajn. Ovaj lek je u fazi 2 kliničkih ispitivanja za poremećaje spavanja.^[4]

Ovaj lek je sličan ACT-078573, koji je razio Aktelion. GlaksoSmitKlajn je prekinuo dalja klinička ispitivanja almoreksanta zbog nuspojava.^[5]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ „Clinical trials to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on subjects with primary insomnia”.
↑ „Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1), ClinicalTrials.gov”. Pristupljeno 3. 02. 2010.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

Šablon:Neuropeptidni ligandi

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] „Clinical trials to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on subjects with primary insomnia”.

[5] „Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1), ClinicalTrials.gov”. Pristupljeno 3. 02. 2010.

[4]

[1]

[2]

[3]

[5]